Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05415709 · ClinicalTrials.gov registry record · Early Phase 1
Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer
A Early Phase 1 study of Ovarian Endometrioid Adenocarcinoma and Fallopian Tube Endometrioid Adenocarcinoma, sponsored by Ohio State University Comprehensive Cancer Center.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 45
- Enrollment target
- 1
- Study location
NCT05415709: Recruiting Early Phase 1 study of Ovarian Endometrioid Adenocarcinoma and Fallopian Tube Endometrioid Adenocarcinoma, sponsored by Ohio State University Comprehensive Cancer Center.
NCT05415709 is a Early Phase 1 study of Ovarian Endometrioid Adenocarcinoma and Fallopian Tube Endometrioid Adenocarcinoma that is actively recruiting participants, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 45 participants, below the 299-participant average among 15 other Ovarian Endometrioid Adenocarcinoma trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05415709, a Early Phase 1 study of Ovarian Endometrioid Adenocarcinoma and Fallopian Tube Endometrioid Adenocarcinoma, is actively recruiting participants, sponsored by Ohio State University Comprehensive Cancer Center.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I trial studies the side effects of hyperthermic intraepithelial chemotherapy with cisplatin after surgery or cisplatin before surgery in treating patients with stage III or IV ovarian, fallopian tube or peritoneal cancer receiving chemotherapy before surgery. Hyperthermic intraepithelial chemotherapy involves the infusion of heated cytotoxic chemotherapy that circulates into the abdominal cavity at the time of surgery. Chemotherapy drugs, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving hyperthermic intraepithelial chemotherapy with cisplatin after surgery or cisplatin before surgery may kill more tumor cells compared to usual care.
Primary Outcome
Defined by Common Terminology Criteria for Adverse Events (CTCAE) version (v)5.0.
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Cisplatin
- DRUG Paclitaxel
- PROCEDURE Cytoreductive Surgery
- DRUG Hyperthermic Intraperitoneal Chemotherapy
Study Locations (1)
Ohio
- Ohio State University Comprehensive Cancer Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2022-06-13 |
| Est. Completion | 2026-12-31 |
| Phase | Early Phase 1 |
What NCT05415709 shows while recruiting
NCT05415709 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 299-participant average among 15 other Ovarian Endometrioid Adenocarcinoma trials with a reported enrollment target (85% lower).
The record links to 10 conditions, with Ovarian Endometrioid Adenocarcinoma appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.
NCT05415709 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT05415709 about?
NCT05415709 is a clinical study titled "Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer". This phase I trial studies the side effects of hyperthermic intraepithelial chemotherapy with cisplatin after surgery or cisplatin before surgery in treating patients with stage III or IV ovarian, fallopian tube or peritoneal cancer receiving chemotherapy before surgery. Hyperthermic intraepithelial...
What is the current status of trial NCT05415709?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 45 participants. The study started on 2022-06-13. Estimated completion is 2026-12-31.
What conditions does trial NCT05415709 study?
This clinical trial studies the following conditions: Ovarian Endometrioid Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Stage III Ovarian Cancer AJCC v8, Fallopian Tube Serous Adenocarcinoma, Ovarian Serous Adenocarcinoma.
What interventions are being tested in trial NCT05415709?
The interventions under investigation include: Carboplatin (DRUG), Cisplatin (DRUG), Paclitaxel (DRUG), Cytoreductive Surgery (PROCEDURE), Hyperthermic Intraperitoneal Chemotherapy (DRUG).
Who is sponsoring clinical trial NCT05415709?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05415709 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Endometrioid Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05415709's enrollment target sits among peer trials
45 11th of 15 higher than 4 of 15 other Ovarian Endometrioid Adenocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ovarian Endometrioid Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
RECRUITING · Phase 3
-
APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion
RECRUITING · Phase 2
-
Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
ACTIVE NOT RECRUITING · Phase 3
-
MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI